Zenas BioPharma, Inc. (ZBIO) Stock Forecast & Price Target

Compare

134 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ZBIO Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Zenas

BioPharma, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ZBIO Stock 12 Month Forecast

Average Price Target

$45.40

▲(12.02% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Zenas BioPharma, Inc. in the last 3 months. The average price target is $45.40 with a high forecast of $55.00 and a low forecast of $37.00. The average price target represents a 12.02% change from the last price of $40.53.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","31":"$31","56":"$56","18.5":"$18.5","43.5":"$43.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$55.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$45.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$37.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,18.5,31,43.5,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.25,33.07692307692308,34.90384615384615,36.73076923076923,38.55769230769231,40.38461538461539,42.21153846153846,44.03846153846154,45.86538461538461,47.69230769230769,49.519230769230774,51.34615384615385,53.17307692307692,{"y":55,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.25,32.33846153846154,33.426923076923075,34.51538461538462,35.603846153846156,36.69230769230769,37.78076923076923,38.86923076923077,39.957692307692305,41.04615384615384,42.13461538461539,43.223076923076924,44.31153846153846,{"y":45.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.25,31.692307692307693,32.13461538461539,32.57692307692308,33.01923076923077,33.46153846153846,33.90384615384615,34.34615384615385,34.78846153846154,35.23076923076923,35.67307692307692,36.11538461538461,36.55769230769231,{"y":37,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.19,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.02,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.01,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.06,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.14,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.52,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.12,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$55.00

Average Price Target$45.40

Lowest Price Target$37.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Cory Kasimov

Evercore ISI

$55

Buy

35.70%

Upside

Initiated

11/26/25

Zenas BioPharma, Inc. (ZBIO) Initiated with a Buy at Evercore ISI

Matthew Caufield

H.C. Wainwright

$30→$44

Buy

8.56%

Upside

Reiterated

11/13/25

Zenas BioPharma's Promising Autoimmune Platform and Buy Rating Reinforced by Advancements in Obexelimab and Orelabrutinib Trials

Yigal Nochomovitz

Citi

$46

Buy

13.50%

Upside

Assigned

11/13/25

Optimistic Buy Rating for Zenas BioPharma Driven by Promising Clinical Trials and Strong Financial Position

Judah Frommer

Morgan Stanley

$34→$37

Buy

-8.71%

Downside

Reiterated

11/13/25

Zenas BioPharma, Inc.: Promising Outlook with Positive Clinical Results and Strong Financial Position Supporting Buy Rating

Martin Fan

Wedbush

$45

Buy

11.03%

Upside

Initiated

10/27/25

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$45

Buy

11.03%

Upside

Reiterated

07/28/25

Zenas BioPharma, Inc. (ZBIO) Gets a Buy from Guggenheim

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$45

Buy

11.03%

Upside

Reiterated

05/15/25

Andy Chen

Wolfe Research

$19

Buy

-53.12%

Downside

Initiated

02/03/25

Zenas BioPharma initiated with an Outperform at Wolfe ResearchZenas BioPharma initiated with an Outperform at Wolfe Research

Roger Song

Jefferies

$35

Buy

-13.64%

Downside

Assigned

01/10/25

Zenas BioPharma: Promising Developments and Strong Fundamentals Amid Market Disconnect

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Cory Kasimov

Evercore ISI

$55

Buy

35.70%

Upside

Initiated

11/26/25

Zenas BioPharma, Inc. (ZBIO) Initiated with a Buy at Evercore ISI

Matthew Caufield

H.C. Wainwright

$30→$44

Buy

8.56%

Upside

Reiterated

11/13/25

Zenas BioPharma's Promising Autoimmune Platform and Buy Rating Reinforced by Advancements in Obexelimab and Orelabrutinib Trials

Yigal Nochomovitz

Citi

$46

Buy

13.50%

Upside

Assigned

11/13/25

Optimistic Buy Rating for Zenas BioPharma Driven by Promising Clinical Trials and Strong Financial Position

Judah Frommer

Morgan Stanley

$34→$37

Buy

-8.71%

Downside

Reiterated

11/13/25

Zenas BioPharma, Inc.: Promising Outlook with Positive Clinical Results and Strong Financial Position Supporting Buy Rating

Martin Fan

Wedbush

$45

Buy

11.03%

Upside

Initiated

10/27/25

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$45

Buy

11.03%

Upside

Reiterated

07/28/25

Zenas BioPharma, Inc. (ZBIO) Gets a Buy from Guggenheim

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$45

Buy

11.03%

Upside

Reiterated

05/15/25

Andy Chen

Wolfe Research

$19

Buy

-53.12%

Downside

Initiated

02/03/25

Zenas BioPharma initiated with an Outperform at Wolfe ResearchZenas BioPharma initiated with an Outperform at Wolfe Research

Roger Song

Jefferies

$35

Buy

-13.64%

Downside

Assigned

01/10/25

Zenas BioPharma: Promising Developments and Strong Fundamentals Amid Market Disconnect

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zenas BioPharma, Inc.

1 Month

xxx

Success Rate

4/5 ratings generated profit

Average Return

+22.00%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +22.00% per trade.

3 Months

xxx

Success Rate

4/5 ratings generated profit

Average Return

+68.08%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +68.08% per trade.

1 Year

Matthew CaufieldH.C. Wainwright

Success Rate

5/6 ratings generated profit

Average Return

+164.32%

reiterated a buy rating 17 days ago

Copying Matthew Caufield's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +164.32% per trade.

2 Years

xxx

Success Rate

5/6 ratings generated profit

Average Return

+164.32%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +164.32% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZBIO Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ZBIO has received 13 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. ZBIO average Analyst price target in the past 3 months is 45.40.

Each month's total comprises the sum of three months' worth of ratings.

ZBIO Financial Forecast

ZBIO Earnings Forecast

Next quarter’s earnings estimate for ZBIO is -$1.04 with a range of -$1.38 to -$0.21. The previous quarter’s EPS was -$1.25. ZBIO beat its EPS estimate 33.33% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ZBIO has Outperformed its overall industry.

ZBIO Sales Forecast

Next quarter’s sales forecast for ZBIO is $8.00M with a range of $0.00 to $40.00M. The previous quarter’s sales results were $0.00. ZBIO beat its sales estimates 33.33% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ZBIO has Outperformed its overall industry.

ZBIO Stock Forecast FAQ

What is ZBIO’s average 12-month price target, according to analysts?

Based on analyst ratings, Zenas BioPharma, Inc.’s 12-month average price target is 45.40.

What is ZBIO’s upside potential, based on the analysts’ average price target?

Zenas BioPharma, Inc. has 12.02% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ZBIO a Buy, Sell or Hold?

Zenas BioPharma, Inc. has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Zenas BioPharma, Inc.’s price target?

The average price target for Zenas BioPharma, Inc. is 45.40. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $55.00 ,the lowest forecast is $37.00. The average price target represents 12.02% Increase from the current price of $40.53.

What do analysts say about Zenas BioPharma, Inc.?

Zenas BioPharma, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of ZBIO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Zenas BioPharma, Inc. (ZBIO) Stock Forecast & Price Target

ZBIO Analyst Ratings

ZBIO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Zenas BioPharma, Inc.

ZBIO Analyst Recommendation Trends

ZBIO Financial Forecast

ZBIO Earnings Forecast

ZBIO Sales Forecast

ZBIO Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts